RT Journal Article SR Electronic T1 Human biodistribution and radiation dosimetry of the demyelination tracer [18F]3F4AP JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2022.05.21.22275275 DO 10.1101/2022.05.21.22275275 A1 Pedro Brugarolas A1 Moses Q. Wilks A1 Jacqueline Noel A1 Julia-Ann Kaiser A1 Danielle R. Vesper A1 Karla M. Ramos-Torres A1 Nicolas J. Guehl A1 Marina T. Macdonald-Soccorso A1 Peter A. Rice A1 Daniel L. Yokell A1 Ruth Lim A1 Marc D. Normandin A1 Georges El Fakhri YR 2022 UL http://medrxiv.org/content/early/2022/05/23/2022.05.21.22275275.abstract AB Purpose [18F]3F4AP is a novel PET radiotracer that targets voltage-gated potassium (K+) channels and has shown promise for imaging demyelinated lesions in animal models of neurological diseases. This study aimed to evaluate the biodistribution, safety and radiation dosimetry of [18F]3F4AP in healthy human volunteers.Methods Four healthy volunteers (2 female) underwent a 4-hour dynamic PET scan from cranial vertex to mid-thigh using multiple bed positions after administration of 368 ± 17.9 MBq (9.94 ± 0.48 mCi) of [18F]3F4AP was produced in a cGMP laboratory under IND authorization from the FDA. Volumes of interest for relevant organs were manually drawn guided by the CT and PET images and time-activity curves (TACs) were extracted. Radiation dosimetry was estimated from the integrated TACs using OLINDA software. Safety assessments included measuring vital signs immediately before and after the scan, monitoring for adverse events, as well as obtaining a comprehensive metabolic panel (CMP) and electrocardiogram (ECG) within 30 days before and after the scan. The study was approved by the institutional review board (IRB) and registered at clinicaltrials.gov (NCT04710550) before commencement.Results [18F]3F4AP distributed throughout the body with the highest levels of activity in the kidneys, urinary bladder, stomach, liver, spleen and brain and with low accumulation in muscle and fat. The tracer cleared quickly from circulation and from most organs. The clearance of the tracer was noticeably faster than previously reported clearance in nonhuman primates (NHPs). The average effective dose (ED) across all subjects was 12.1 ± 2.2 µSv/MBq, which is lower than the estimated ED from the NHP studies (21.6 ± 0.6 µSv/MBq) as well as the ED of other fluorine-18 radiotracers such as [18F]FDG (∼20 µSv/MBq). No differences in ED between males and females were observed. No substantial changes in safety assessments or adverse events were recorded.Conclusion The biodistribution and radiation dosimetry of [18F]3F4AP in humans is reported for the first time. The average total ED across four subjects was lower than most 18F-labeled PET tracers. The tracer and study procedures were well tolerated and no adverse events occurred.Competing Interest StatementPB has a financial interest in Fuzionaire Diagnostics and the University of Chicago. PB is a named inventor of patents related to [18F]3F4AP owned by the University of Chicago and licensed to Fuzionaire Diagnostics. PB interests were reviewed and are managed by MGH and Mass General Brigham in accordance with their conflict of interest policies. The other authors declare no conflict of interests.Clinical TrialNCT04710550Funding StatementThis study was partially supported by an Innovation Award from the Polsky Center at the University of Chicago (PB), NIH R01NS114066 (PB), P41EB022544 (GEF), S10OD026987 (MDN, GEF) and S10OD018035 (MDN, GEF).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Institutional Review Board at the Massachusetts General Hospital and registered in clinicaltrials.gov prior to initiation of the study (NCT04710550). [18F]3F4AP was administered under an investigational new drug (IND) authorization from the U.S. Food and Drug Administration (FDA).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated during and analyzed during the current study are available from the corresponding author on reasonable request.